Tonix Pharmaceut Financials
Tonix Pharmaceut (TNXP) reported $29.1M in revenue over the twelve months to Jun 30, 2026, up 196.0% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Tonix’s development-stage model produces persistent cash needs, with expansion financed mainly through external funding rather than operations.
The gross-margin rebound from23.1% in FY2024 to49.3% in FY2025 improved the economics of reported sales. Yet operating cash flow remained-$99.8M , showing that better gross profitability has not translated into self-funding operations while the broader cost base remains substantial.
FY2025 R&D and SG&A spending totaled
Financing cash flow of
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Tonix Pharmaceut's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Tonix Pharmaceut scores -0.54, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($233.1M) relative to total liabilities ($32.0M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Tonix Pharmaceut passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
Tonix Pharmaceut reported a net loss of $124.0M while operations used $99.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Tonix Pharmaceut reported an operating loss of $125.7M against $89K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Tonix Pharmaceut generated $13.1M in revenue in fiscal year 2025. This represents an increase of 29.8% from the prior year.
Tonix Pharmaceut's EBITDA was -$123.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 7.1% from the prior year.
Tonix Pharmaceut reported -$124.0M in net income in fiscal year 2025. This represents an increase of 4.6% from the prior year.
Cash & Balance Sheet
Tonix Pharmaceut recorded an outflow of $103.2M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents a decrease of 69.1% from the prior year.
Tonix Pharmaceut held $207.6M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
Tonix Pharmaceut's gross margin was 49.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 26.3 percentage points from the prior year.
Tonix Pharmaceut's ROE was -50.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 42.6 percentage points from the prior year.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Tonix Pharmaceut invested $44.5M in research and development in fiscal year 2025. This represents an increase of 11.3% from the prior year.
Tonix Pharmaceut spent $13.8M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding.
Tonix Pharmaceut invested $3.4M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 2707.5% from the prior year.
TNXP Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $13.5M+96.9% | $6.9M+27.6% | $5.4M+63.8% | $3.3M+64.7% | $2.0M-17.7% | $2.4M-5.9% | $2.6M-8.5% | $2.8M |
| Cost of Revenue | $703K-55.4% | $1.6M+49.1% | $1.1M-22.6% | $1.4M-58.2% | $3.3M+247.0% | $943K-20.3% | $1.2M-23.9% | $1.6M |
| Gross Profit | $12.8M+142.3% | $5.3M+22.3% | $4.3M+125.3% | $1.9M+250.9% | -$1.3M-185.7% | $1.5M+6.2% | $1.4M+10.4% | $1.3M |
| R&D Expenses | $19.4M+6.6% | $18.2M+7.5% | $16.9M+82.4% | $9.3M-14.1% | $10.8M+45.5% | $7.4M-10.4% | $8.3M-9.0% | $9.1M |
| SG&A Expenses | $36.0M+25.6% | $28.6M-19.8% | $35.7M+38.8% | $25.7M+58.6% | $16.2M+60.4% | $10.1M-35.2% | $15.6M+102.2% | $7.7M |
| Operating Income | -$42.5M-2.4% | -$41.5M+14.0% | -$48.3M-46.0% | -$33.1M-16.9% | -$28.3M-76.3% | -$16.1M+28.6% | -$22.5M-44.5% | -$15.6M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $301K |
| Net Income | -$40.6M-0.9% | -$40.2M+14.3% | -$46.9M-46.5% | -$32.0M-13.2% | -$28.3M-68.0% | -$16.8M+23.9% | -$22.1M-55.5% | -$14.2M |
| EPS (Diluted) | -$2.44+16.7% | -$2.93+29.4% | -$4.15-15.6% | -$3.59+7.0% | -$3.86-35.9% | -$2.84-101.0% | $289.57 | -$22.68 |
Not reported in any period shown, so not listed: Income Tax.
TNXP Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $254.1M-1.5% | $257.9M-6.9% | $277.2M+9.8% | $252.4M+34.7% | $187.4M-2.9% | $192.9M+18.4% | $162.9M+71.5% | $95.0M |
| Current Assets | $203.4M-1.8% | $207.2M-9.5% | $228.9M+10.0% | $208.1M+45.0% | $143.5M-4.0% | $149.6M+25.7% | $119.0M+135.4% | $50.5M |
| Cash & Equivalents | $176.2M-5.0% | $185.5M-10.7% | $207.6M+9.3% | $190.1M+51.6% | $125.3M-4.8% | $131.7M+33.3% | $98.8M+249.9% | $28.2M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | $8.4M+6.0% | $7.9M |
| Accounts Receivable | $11.8M+33.8% | $8.8M+40.6% | $6.3M+80.1% | $3.5M+50.0% | $2.3M-30.0% | $3.3M-10.1% | $3.7M-8.2% | $4.0M |
| Total Liabilities | $31.8M+3.4% | $30.8M-3.9% | $32.0M+50.4% | $21.3M+10.0% | $19.4M+55.2% | $12.5M-46.5% | $23.3M+12.3% | $20.8M |
| Current Liabilities | $30.8M+3.8% | $29.6M-3.9% | $30.8M+46.6% | $21.0M+10.3% | $19.1M+56.9% | $12.1M-33.7% | $18.3M+20.6% | $15.2M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | $4.7M-9.8% | $5.2M |
| Total Equity | $222.3M-2.1% | $227.1M-7.3% | $245.2M+6.1% | $231.1M+37.6% | $168.0M-6.9% | $180.4M+29.3% | $139.6M+88.1% | $74.2M |
| Retained Earnings | -$935.5M-4.5% | -$894.9M-4.7% | -$854.7M-5.8% | -$807.8M-4.1% | -$775.8M-3.8% | -$747.5M-2.3% | -$730.7M-3.1% | -$708.6M |
Not reported in any period shown, so not listed: Goodwill.
TNXP Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$42.2M+0.2% | -$42.3M-6.7% | -$39.6M-37.8% | -$28.8M-94.0% | -$14.8M+10.5% | -$16.6M-13.3% | -$14.6M+22.2% | -$18.8M |
| Capital Expenditures | $587K-65.3% | $1.7M-9.7% | $1.9M+94.8% | $962K+82.5% | $527K+8683.3% | $6K+100.0% | $3K-66.7% | $9K |
| Free Cash Flow | -$42.8M+2.7% | -$44.0M-6.0% | -$41.5M-39.6% | -$29.7M-93.6% | -$15.4M+7.4% | -$16.6M-13.3% | -$14.6M+22.2% | -$18.8M |
| Investing Cash Flow | -$587K+65.3% | -$1.7M-65.7% | -$1.0M-6.1% | -$962K+62.1% | -$2.5M-42216.7% | -$6K-100.0% | -$3K+66.7% | -$9K |
| Financing Cash Flow | $33.5M+65.8% | $20.2M-65.8% | $59.1M-37.7% | $94.9M+762.9% | $11.0M-77.8% | $49.5M-41.8% | $85.2M+98.5% | $42.9M |
| Share Buybacks | N/A | N/A | $7.8M | $0-100.0% | $2.9M-4.8% | $3.0M | N/A | N/A |
Not reported in any period shown, so not listed: Dividends Paid.
TNXP Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 94.8%+17.8pp | 77.1%-3.3pp | 80.4%+21.9pp | 58.5%+122.2pp | -63.8%-124.9pp | 61.2%+7.0pp | 54.2%+9.3pp | 44.9% |
| Operating Margin | -314.1% | -603.9% | -895.8% | -1005.1% | -1416.2% | -660.9% | -870.6% | -551.2% |
| Net Margin | -299.4% | -584.4% | -870.3% | -972.9% | -1415.0% | -692.8% | -856.2% | -503.7% |
| Return on Equity | -18.2%-0.5pp | -17.7%+1.4pp | -19.1%-5.3pp | -13.9%+3.0pp | -16.8%-7.5pp | -9.3%+6.5pp | -15.8%+3.3pp | -19.1% |
| Return on Assets | -16.0%-0.4pp | -15.6%+1.3pp | -16.9%-4.2pp | -12.7%+2.4pp | -15.1%-6.4pp | -8.7%+4.8pp | -13.6%+1.4pp | -15.0% |
| Current Ratio | 6.61-0.4x | 6.99-0.4x | 7.42-2.5x | 9.89+2.4x | 7.53-4.8x | 12.31+5.8x | 6.50+3.2x | 3.33 |
| Debt-to-Equity | 0.140.0x | 0.140.0x | 0.130.0x | 0.090.0x | 0.120.0x | 0.070.0x | 0.030.0x | 0.07 |
| FCF Margin | -316.2% | -639.9% | -770.4% | -904.1% | -768.8% | -682.8% | -566.7% | -666.5% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Tonix Pharmaceut Ranks
Frequently Asked Questions
What is Tonix Pharmaceut's annual revenue?
Tonix Pharmaceut (TNXP) reported $13.1M in total revenue for fiscal year 2025. This represents a 29.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Tonix Pharmaceut's revenue growing?
Tonix Pharmaceut (TNXP) revenue grew by 29.8% year-over-year, from $10.1M to $13.1M in fiscal year 2025.
Is Tonix Pharmaceut profitable?
No, Tonix Pharmaceut (TNXP) reported a net income of -$124.0M in fiscal year 2025.
What is Tonix Pharmaceut's EBITDA?
Tonix Pharmaceut (TNXP) had EBITDA of -$123.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Tonix Pharmaceut's gross margin?
Tonix Pharmaceut (TNXP) had a gross margin of 49.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Tonix Pharmaceut's return on equity (ROE)?
Tonix Pharmaceut (TNXP) has a return on equity of -50.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Tonix Pharmaceut's free cash flow?
Tonix Pharmaceut (TNXP) recorded an outflow of $103.2M in free cash flow during fiscal year 2025. This represents a -69.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Tonix Pharmaceut's operating cash flow?
Tonix Pharmaceut (TNXP) recorded an outflow of $99.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Tonix Pharmaceut's total assets?
Tonix Pharmaceut (TNXP) had $277.2M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Tonix Pharmaceut's capital expenditures?
Tonix Pharmaceut (TNXP) invested $3.4M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Tonix Pharmaceut spend on research and development?
Tonix Pharmaceut (TNXP) invested $44.5M in research and development during fiscal year 2025.
What is Tonix Pharmaceut's current ratio?
Tonix Pharmaceut (TNXP) had a current ratio of 7.42 as of fiscal year 2025, which is generally considered healthy.
What is Tonix Pharmaceut's debt-to-equity ratio?
Tonix Pharmaceut (TNXP) had a debt-to-equity ratio of 0.13 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Tonix Pharmaceut's return on assets (ROA)?
Tonix Pharmaceut (TNXP) had a return on assets of -44.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
How does Tonix Pharmaceut's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Tonix Pharmaceut (TNXP) held $207.6M in cash, cash equivalents and investments, and reported an operating cash outflow of $99.8M over that year. Dividing the one by the other, the reported balance equals about 25 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Tonix Pharmaceut's Altman Z-Score?
Tonix Pharmaceut (TNXP) has an Altman Z-Score of -0.54, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Tonix Pharmaceut's Piotroski F-Score?
Tonix Pharmaceut (TNXP) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Tonix Pharmaceut's earnings high quality?
Tonix Pharmaceut (TNXP) reported a net loss of $124.0M while operations used $99.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Tonix Pharmaceut cover its interest payments?
Tonix Pharmaceut (TNXP) reported an operating loss of $125.7M against $89K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Tonix Pharmaceut?
Tonix Pharmaceut (TNXP) scores 70 out of 100 on our Financial Health Score, indicating strong standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.